EA201170338A1 - METHOD AND COMPOSITION FOR THE TREATMENT OF ADVERSE BIOLOGICAL CONDITIONS - Google Patents

METHOD AND COMPOSITION FOR THE TREATMENT OF ADVERSE BIOLOGICAL CONDITIONS

Info

Publication number
EA201170338A1
EA201170338A1 EA201170338A EA201170338A EA201170338A1 EA 201170338 A1 EA201170338 A1 EA 201170338A1 EA 201170338 A EA201170338 A EA 201170338A EA 201170338 A EA201170338 A EA 201170338A EA 201170338 A1 EA201170338 A1 EA 201170338A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
biological conditions
composition
adverse biological
presented
Prior art date
Application number
EA201170338A
Other languages
Russian (ru)
Inventor
Раджив Бхушан
Джерри Б. Джин
Амит Госвами
Original Assignee
Лайвайонекс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лайвайонекс Инк. filed Critical Лайвайонекс Инк.
Publication of EA201170338A1 publication Critical patent/EA201170338A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлен способ лечения неблагоприятных биологических состояний, где биологически активное средство, такое как биологическая макромолекула, например нуклеиновая кислота или пептидное соединение, вводят нуждающемуся в таком лечении индивидууму в составе, содержащем усилитель транспорта со структурой формулы (I), где Q, Rи Rявляются такими, как определено в настоящем документе. Характерным и предпочтительным усилителем транспорта является метилсульфонилметан (MSM). Также представлены составы.SUBSTANCE: method is presented for treatment of unfavorable biological conditions, where a biologically active agent, such as a biological macromolecule, for example a nucleic acid or a peptide compound, is administered to an individual in need of such treatment in a composition containing a transport enhancer with the structure of formula (I), where Q, R and R are such as defined herein. A characteristic and preferred transport enhancer is methylsulfonylmethane (MSM). Also presented compositions.

EA201170338A 2008-08-15 2009-08-17 METHOD AND COMPOSITION FOR THE TREATMENT OF ADVERSE BIOLOGICAL CONDITIONS EA201170338A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18906008P 2008-08-15 2008-08-15
PCT/US2009/004709 WO2010019276A2 (en) 2008-08-15 2009-08-17 Method and formulation for treating adverse biological conditions

Publications (1)

Publication Number Publication Date
EA201170338A1 true EA201170338A1 (en) 2011-10-31

Family

ID=41669540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170338A EA201170338A1 (en) 2008-08-15 2009-08-17 METHOD AND COMPOSITION FOR THE TREATMENT OF ADVERSE BIOLOGICAL CONDITIONS

Country Status (5)

Country Link
US (1) US20100209419A1 (en)
EP (1) EP2328570A4 (en)
AU (1) AU2009282456A1 (en)
EA (1) EA201170338A1 (en)
WO (1) WO2010019276A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934448A1 (en) 2012-12-20 2014-06-26 Rajiv Bhushan Antimicrobial compositions
US20220047614A1 (en) * 2016-02-25 2022-02-17 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN112307562B (en) * 2020-10-30 2022-03-01 泉州装备制造研究所 Method for assembling complex parts on large-scale airplane by combining thermal deformation and gravity deformation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752658B2 (en) * 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
EP1539244A1 (en) * 2002-06-27 2005-06-15 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20090053197A1 (en) * 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
JP2010519196A (en) * 2007-02-15 2010-06-03 ダーマ−ヤング リミテッド Compositions and methods for enhancing transmucosal delivery

Also Published As

Publication number Publication date
US20100209419A1 (en) 2010-08-19
EP2328570A2 (en) 2011-06-08
WO2010019276A3 (en) 2010-06-03
AU2009282456A1 (en) 2010-02-18
EP2328570A4 (en) 2012-10-24
WO2010019276A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
GEP20146122B (en) Pharmaceutical composition
UA107174C2 (en) THE Crystalline Forms of Saxagliptin and the Process of Obtaining It (OPTIONS)
EA200601279A1 (en) PIPERIDINILKARBONILPYRROLIDINES AND THEIR APPLICATION AS AGANISTS OF MELANOCORTIN
EA200971104A1 (en) Derivatives of benzimidazole
EA201171333A1 (en) CRYSTAL SOLVATES AND COMPLEXES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLYCITOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATMENT
EA201170289A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AT LOW CONCENTRATION OF IMPURITIES
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
EA201001368A1 (en) HETEROCYCLIC UREA DERIVATIVES AND METHODS OF THEIR APPLICATION-211
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
BRPI0600194A (en) docetaxel-containing pharmaceutical compositions and a degradation inhibitor and process for obtaining same
EA201100750A1 (en) SUBSTITUTED DIOXOPIPERIDINYL-PHTHALIMIDE DERIVATIVES
EA200801287A1 (en) Pyrimidine derivatives for the treatment of anomalous cell growth
EA201270560A1 (en) SPYROPYPERIDINE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS FOR TREATMENT OF DIABETES
EA200702593A1 (en) HIGHLY CONCENTRATED COMPOSITIONS APPLICABLE FOR THE FIGHT AGAINST ECO AND END-PARASITES
TW200611694A (en) Liquid composition for veterinary medicine, process for its preparation and use thereof
EP3020397A3 (en) Process for the manufacture of ajoene derivatives
EA200702375A1 (en) UREA DERIVATIVES, METHODS FOR THEIR RECEPTION AND APPLICATION
BR112012014721A2 (en) growth hormone composition
EA201001859A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AND METHODS FOR THEIR APPLICATION
EA201001858A1 (en) HETEROCYCLIC DERIVATIVES OF UREA FOR THE TREATMENT OF BACTERIAL INFECTIONS
ATE493110T1 (en) COSMETIC COMPOSITION FOR STIMULATING THE SYNTHESIS OF BASAL MEMBRANE PROTEINS
EA201170338A1 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF ADVERSE BIOLOGICAL CONDITIONS
RU2012114820A (en) THE MODIFIED ERYTHROPOETIN TO WHICH THE WATER-SOLUBLE LENGTH CHAIN MOLECULE IS ATTACHED
BRPI0614434B1 (en) oral liquid composition comprising arginine and r-alpha-lipoic acid
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof